1. patient is at high-risk for severe covid-19 due to co-morbidities defined as: 1. underlying lung disease such as emphysema, chronic lung disease, copd, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (o2) support; 2. immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; 3. immunosuppressive therapy, including but not limited to the following: * corticosteroids (except topical corticosteroids); * interleukin (il)-6 or tumor necrosis factor alpha (tnfα) blockade; * other immunotherapies. 2. patient with the following signs of abnormal organ or bone marrow function as defined below: * ast(sgot) and/or alt(sgpt) \> 3 x upper limit of normal (uln); * serum (total) bilirubin \> 1.5 x uln; * creatinine clearance ≤ 30 ml/min (by modification of diet in renal disease (mdrd) formula); * hemoglobin \< 9 g/dl; * thrombocytes ≤ 75.000/ul; * absolute neutrophil count (anc) ≤ 1.500/ul; * prothrombin time (pt) or activated partial thromboplastin (aptt) time \>1.5 × uln; 3. patient has been admitted to the (icu); 4. patients with qt prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); 5. patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or dmso; 6. pregnant (positive pregnancy test) or breast-feeding female patients; 7. women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; 8. participation in other covid-19 studies involving experimental treatments or vaccines for covid-19. participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; 9. patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; 10. vulnerable populations such as those currently incarcerated or homeless; 11. any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.

1. patient is at high-risk for severe covid-19 due to co-morbidities defined as: 1. underlying lung disease such as emphysema, chronic lung disease, copd, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (o2) support; 2. immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; 3. immunosuppressive therapy, including but not limited to the following: * corticosteroids (except topical corticosteroids); * interleukin (il)-6 or tumor necrosis factor alpha (tnfα) blockade; * other immunotherapies. 2. patient with the following signs of abnormal organ or bone marrow function as defined below: * ast(sgot) and/or alt(sgpt) \> 3 x upper limit of normal (uln); * serum (total) bilirubin \> 1.5 x uln; * creatinine clearance ≤ 30 ml/min (by modification of diet in renal disease (mdrd) formula); * hemoglobin \< 9 g/dl; * thrombocytes ≤ 75.000/ul; * absolute neutrophil count (anc) ≤ 1.500/ul; * prothrombin time (pt) or activated partial thromboplastin (aptt) time \>1.5 × uln; 3. patient has been admitted to the (icu); 4. patients with qt prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); 5. patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or dmso; 6. pregnant (positive pregnancy test) or breast-feeding female patients; 7. women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; 8. participation in other covid-19 studies involving experimental treatments or vaccines for covid-19. participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; 9. patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; 10. vulnerable populations such as those currently incarcerated or homeless; 11. any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.

patient is at high-risk for severe covid-19 due to co-morbidities defined as: underlying lung disease such as emphysema, chronic lung disease, copd, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (o2) support; immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; immunosuppressive therapy, including but not limited to the following: corticosteroids (except topical corticosteroids); interleukin (il)-6 or tumor necrosis factor alpha (tnfα) blockade; other immunotherapies. patient with the following signs of abnormal organ or bone marrow function as defined below: ast(sgot) and/or alt(sgpt) > 3 x upper limit of normal (uln); serum (total) bilirubin > 1.5 x uln; creatinine clearance ≤ 30 ml/min (by modification of diet in renal disease (mdrd) formula); hemoglobin < 9 g/dl; thrombocytes ≤ 75.000/ul; absolute neutrophil count (anc) ≤ 1.500/ul; prothrombin time (pt) or activated partial thromboplastin (aptt) time >1.5 × uln; patient has been admitted to the (icu); patients with qt prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or dmso; pregnant (positive pregnancy test) or breast-feeding female patients; women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; participation in other covid-19 studies involving experimental treatments or vaccines for covid-19. participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; vulnerable populations such as those currently incarcerated or homeless; any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.

patient is at high-risk for severe covid-19 due to co-morbidities defined as: underlying lung disease such as emphysema, chronic lung disease, copd, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (o2) support; immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; immunosuppressive therapy, including but not limited to the following: corticosteroids (except topical corticosteroids); interleukin (il)-6 or tumor necrosis factor alpha (tnfα) blockade; other immunotherapies. patient with the following signs of abnormal organ or bone marrow function as defined below: ast(sgot) and/or alt(sgpt) > 3 x upper limit of normal (uln); serum (total) bilirubin > 1.5 x uln; creatinine clearance ≤ 30 ml/min (by modification of diet in renal disease (mdrd) formula); hemoglobin < 9 g/dl; thrombocytes ≤ 75.000/ul; absolute neutrophil count (anc) ≤ 1.500/ul; prothrombin time (pt) or activated partial thromboplastin (aptt) time >1.5 × uln; patient has been admitted to the (icu); patients with qt prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or dmso; pregnant (positive pregnancy test) or breast-feeding female patients; women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; participation in other covid-19 studies involving experimental treatments or vaccines for covid-19. participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; vulnerable populations such as those currently incarcerated or homeless; any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.

1. patient is at high-risk for severe covid-19 due to co-morbidities defined as: 1. underlying lung disease such as emphysema, chronic lung disease, copd, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (o2) support; 2. immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; 3. immunosuppressive therapy, including but not limited to the following: - corticosteroids (except topical corticosteroids); - interleukin (il)-6 or tumor necrosis factor alpha (tnfα) blockade; - other immunotherapies. 2. patient with the following signs of abnormal organ or bone marrow function as defined below: - ast(sgot) and/or alt(sgpt) > 3 x upper limit of normal (uln); - serum (total) bilirubin > 1.5 x uln; - creatinine clearance ≤ 30 ml/min (by modification of diet in renal disease (mdrd) formula); - hemoglobin < 9 g/dl; - thrombocytes ≤ 75.000/ul; - absolute neutrophil count (anc) ≤ 1.500/ul; - prothrombin time (pt) or activated partial thromboplastin (aptt) time >1.5 × uln; 3. patient has been admitted to the (icu); 4. patients with qt prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); 5. patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or dmso; 6. pregnant (positive pregnancy test) or breast-feeding female patients; 7. women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; 8. participation in other covid-19 studies involving experimental treatments or vaccines for covid-19. participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; 9. patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; 10. vulnerable populations such as those currently incarcerated or homeless; 11. any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.

1. patient is at high-risk for severe covid-19 due to co-morbidities defined as: 1. underlying lung disease such as emphysema, chronic lung disease, copd, asthma, chronic bronchiectasis or respiratory failure requiring baseline oxygen (o2) support; 2. immunocompromised host status due to cancer, transplant, or other causes of immunodeficiency; 3. immunosuppressive therapy, including but not limited to the following: - corticosteroids (except topical corticosteroids); - interleukin (il)-6 or tumor necrosis factor alpha (tnfα) blockade; - other immunotherapies. 2. patient with the following signs of abnormal organ or bone marrow function as defined below: - ast(sgot) and/or alt(sgpt) > 3 x upper limit of normal (uln); - serum (total) bilirubin > 1.5 x uln; - creatinine clearance ≤ 30 ml/min (by modification of diet in renal disease (mdrd) formula); - hemoglobin < 9 g/dl; - thrombocytes ≤ 75.000/ul; - absolute neutrophil count (anc) ≤ 1.500/ul; - prothrombin time (pt) or activated partial thromboplastin (aptt) time >1.5 × uln; 3. patient has been admitted to the (icu); 4. patients with qt prolongation, history of "torsades de pointes" or ventricular arrhythmia (if they are scheduled to receive diphenhydramine); 5. patient with a known history of allergic reactions to any constituent of the product, including a known history of allergic reactions to cellular products or dmso; 6. pregnant (positive pregnancy test) or breast-feeding female patients; 7. women of childbearing potential who are sexually active and men who have sexual contact with a female of childbearing potential: not willing to use reliable methods of contraception (oral contraceptives, intrauterine device, hormone implants, contraceptive injection or abstinence) up to 90 days post injection of study medication; 8. participation in other covid-19 studies involving experimental treatments or vaccines for covid-19. participation in other observational studies could be allowed if they do not interfere with protocol compliance or blood draws; 9. patients with a history or current evidence of alcohol or drug abuse or dependence, or recreational use of illicit drugs including use of medical marijuana; 10. vulnerable populations such as those currently incarcerated or homeless; 11. any other condition which in the opinion of the investigator makes the patient ineligible for participation in the study.